Updates are available Correction dated 2025-10-31
Click to view Correction: https://doi.org/10.1038/s41408-025-01403-9
-
Authors
Steinhardt, Maximilian J. https://orcid.org/0000-0003-3644-9187
Schaefers, Christoph
Leypoldt, Lisa B. https://orcid.org/0000-0002-9248-588X
Blau, Igor-Wolfgang
Harzer, Marie https://orcid.org/0009-0002-0763-3823
Zhou, Xiang
Riedhammer, Christine
Kamili, Abdulaziz
Kosch, Ricardo
Topp, Laura S.
Molwitz, Isabel
Gross-Fengels, Nils-Ole
Melzer, Yasmin Fede https://orcid.org/0009-0007-4199-1807
Artzenroth, Jule
Al-Bazaz, Maximilian
Alsdorf, Winfried
Topp, Max S.
Duell, Johannes
Mersi, Julia
Waldschmidt, Johannes
Bokemeyer, Carsten
Einsele, Hermann https://orcid.org/0000-0002-7680-0819
Kortüm, K. Martin https://orcid.org/0000-0002-7011-0286
Weisel, Katja
Rasche, Leo https://orcid.org/0000-0002-9536-9649
- License Information
-
More Information
Article History
Received: 11 March 2025
Revised: 13 June 2025
Accepted: 4 July 2025
First Online: 30 July 2025
Change Date: 24 October 2025
Change Type: Update
Change Details: The original online version of this article was revised: Following the publication of this article, an error was noted in the text of the introduction. The following paragraph:"T-cell redirecting bispecific antibodies (bsABs) and CAR-T cells have shown impressive response rates and progression-free survival (PFS) ..." has been corrected and citation 18 has also been removed.
Change Date: 31 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-025-01403-9
Competing interests
: MJS: Travel funds from and consultancy for Johnson&Johnson outside of the submitted work. CS: Consultancy for Acus Health, Astra Zeneca, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer; honoraria from Abbvie, Astra Zeneca, Janssen-Cilag; other (travel expenses/congress support): Acus Health, Astra Zeneca, Janssen-Cilag, Menarini Stemline, oncopeptides, Sanofi. LBL: Advisory role: GSK, Sanofi, Janssen; Honoraria-payments for specific speeches, seminar presentations, or appearances: Adaptive, AbbVie, Janssen, BMS/Celgene, Pfizer, Sanofi, GSK, Takeda, AstraZeneca; Research funding: Abbvie, GSK (both to the institution); Travel: Sanofi, Oncopeptides, J&J I-WB states no conflicts of interest. MH states no conflicts of interest. XZ states no conflicts of interest. CR received honoraria from Janssen. AK states no conflicts of interest. RK states no conflicts of interest. LST states no conflicts of interest. IM states no conflicts of interest. N-OG-F states no conflicts of interest. YFM states no conflicts of interest. JA: Travel funds from Sanofi. MA-B states no conflicts of interest. WA: Honoraria from GSK, Janssen, Astellas, AstraZeneca. Research Funding: Affimed, Biontech. Consultancy: Janssen, Immatics. ST states no conflicts of interest. JD states no conflicts of interest. JM states no conflicts of interest. JW states no conflicts of interest. CB states no conflicts of interest. HE states no conflicts of interest. KMK states no conflicts of interest. KW states no conflicts of interest. LR states no conflicts of interest.
